Form 6-K ASTRAZENECA PLC For: Sep 01
Tweet
Share
E-mail
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of September 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Admission to Trading - €2.55 billion bond
offering
1 September 2026
Admission to Trading - €2.55 billion bond
offering
In accordance with the Financial Conduct Authority's Prospectus
Rules: Admission to Trading on a Regulated Market (PRM) sourcebook
1.5.2 and 1.5.3R, AstraZeneca PLC announces that its wholly owned
subsidiary AstraZeneca Finance LLC notifies the market that debt
securities have been admitted to trading as follows:
|
Issuer name:
|
AstraZeneca Finance LLC
|
|
Issuer LEI:
|
549300C3HATU4Q460S18
|
|
Regulated market on which the securities have been admitted to
trading:
|
Main Market for listed securities of the London Stock
Exchange
|
|
Name, type and ISIN of the securities:
|
EUR 700,000,000 3.402 per cent. Notes due 1 March 2030, ISIN:
XS3484302206
(Final Terms available at https://www.astrazeneca.com/content/dam/az/Investor_Relations/debt-investors/pdf/AstraZeneca-Final-Terms-2030.pdf)
EUR 600,000,000 3.652 per cent. Notes due 1 September 2032, ISIN:
XS3484302461
(Final Terms available at https://www.astrazeneca.com/content/dam/az/Investor_Relations/debt-investors/pdf/AstraZeneca-Final-Terms-2032.pdf)
EUR 500,000,000 3.923 per cent. Notes due 1 September 2035, ISIN:
XS3484302545
(Final Terms available at https://www.astrazeneca.com/content/dam/az/Investor_Relations/debt-investors/pdf/AstraZeneca-Final-Terms-2035.pdf)
EUR 750,000,000 4.169 per cent. Notes due 1 September 2038, ISIN:
XS3484302628
(Final Terms available at https://www.astrazeneca.com/content/dam/az/Investor_Relations/debt-investors/pdf/AstraZeneca-Final-Terms-2038.pdf)
|
|
Number of securities admitted to trading:
|
Four series:
EUR 700,000,000
EUR 600,000,000
EUR 500,000,000
EUR 750,000,000
in aggregate nominal amount
|
|
Date of admission to trading:
|
1 September 2026
|
|
Date of Prospectus relating to the securities:
|
The base prospectus dated 9 June 2026 (the "Base Prospectus") under which the securities have been issued is
available at:
https://www.astrazeneca.com/content/dam/az/Investor_Relations/debt-investors/pdf/2026/AZ-EMTN-U26-Base-Prospectus.pdf
|
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Disease, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
Disclaimer - Intended Addressees
Please note that the information contained in the Base Prospectus
may be addressed to and/or targeted at persons who are residents of
particular countries (specified in the Base Prospectus) only and is
not intended for use and should not be relied upon by any person
outside these countries and/or to whom the offer contained in the
Base Prospectus is not addressed. Prior to relying on the
information contained in the Base Prospectus, you must ascertain
from the Base Prospectus whether or not you are part of the
intended addressees of the information contained
therein.
Your right to access this service is conditional upon complying
with the above requirement.
EU MiFID II/UK MiFIR (Product Governance) - professionals and
ECPs-only / No EU PRIIPs KID or UK PRIIPs KID/CCI product
summary -
Manufacturer target market (EU MiFID II product governance and UK
MiFIR product governance) is eligible counterparties and
professional clients only (all distribution channels). No EU PRIIPs
key information document (KID) or UK PRIIPs key information
document (KID)/CCI product summary (as defined in the FCA Product
Disclosure Sourcebook (DISC)) has been prepared as the Notes are
not available to retail in the EEA or in the United
Kingdom.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date: 01 September 2026
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves AstraZeneca breast cancer drug Etcamah via accelerated path
- AstraZeneca closes $600M deal for lung cancer drug Zegfrovy
- BofA Securities Reiterates Buy Rating on AstraZeneca (AZN:LN) (AZN)
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
